Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

read more

Vator Securities Unicorn Summit was held on November 27th 2019 at IVA Conferens Center in Stockholm and was attended by over 200 guests.

Click here to watch the presentations

Vator Securities advises SenzaGen on 106 MSEK Directed and Rights Issue

The subscribers in the Directed Share Issue are, amongst other, AP-4 (The Fourth Swedish National Pension Fund), Ålandsbanken Abp, Consensus Asset Management, Kavaljer, Segersta and Thomas Olausson.

read more

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

read more

Vator Securities Sole Bookrunner in Nanoform SEK 106 million private placement

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

read more

Vator Securities advises Empros Pharma on 40 MSEK private placement

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

read more

More News